|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.89 USD | -1.05% |
|
+34.04% | -5.03% |
| 14/05 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
| 13/05 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Exagen Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 45.56 million compared to USD 48.3 million a year ago. Net loss was USD 47.39 million compared to USD 26.85 million a year ago.
Basic loss per share from continuing operations was USD 2.77 compared to USD 1.68 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -5.03% | 32.8M | |
| +19.22% | 84.52B | |
| -27.14% | 72.21B | |
| +4.65% | 27.74B | |
| -6.23% | 17.97B | |
| +1.60% | 17.46B | |
| +3.30% | 15.82B | |
| +7.44% | 13.55B | |
| +9.91% | 13.31B | |
| +73.32% | 13.32B |
EXAGEN INC. 
